A detailed history of Ikarian Capital, LLC transactions in Immunic, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 493,496 shares of IMUX stock, worth $582,325. This represents 0.22% of its overall portfolio holdings.

Number of Shares
493,496
Previous 1,612,378 69.39%
Holding current value
$582,325
Previous $2.13 Million 74.3%
% of portfolio
0.22%
Previous 0.28%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.98 - $1.44 $1.1 Million - $1.61 Million
-1,118,882 Reduced 69.39%
493,496 $547,000
Q1 2024

May 15, 2024

BUY
$1.14 - $1.53 $1.84 Million - $2.47 Million
1,612,378 New
1,612,378 $2.13 Million
Q3 2023

Nov 14, 2023

SELL
$1.35 - $2.87 $270,000 - $574,000
-200,000 Reduced 30.77%
450,000 $661,000
Q4 2022

Feb 14, 2023

BUY
$1.13 - $10.8 $734,499 - $7.02 Million
650,000 New
650,000 $910,000
Q2 2022

Aug 12, 2022

BUY
$3.13 - $12.25 $192,495 - $753,375
61,500 New
61,500 $214,000

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $36.1M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.